Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey.

Lisa K Stamp William John Taylor Angelo Lino Gaffonull null

Published in: The Journal of rheumatology (2020)

Gout is common in people with chronic kidney disease (CKD) and its treatment is frequently suboptimal in this special population due to concerns over adverse events and/or efficacy of medications. There is controversy about the use of urate-lowering therapy (ULT) in those with CKD and lack of agreement about the dosing of allopurinol, the recommended first-line ULT1,2.

Keyphrases

chronic kidney disease
end stage renal disease
uric acid
primary care
emergency department
metabolic syndrome
stem cells